Blood thinner study aims to protect cancer patients from dangerous clots
NCT ID NCT06474182
Summary
This study compares how well a common blood thinner (apixaban) prevents blood clots in two groups: patients newly diagnosed with multiple myeloma (a blood cancer) and patients undergoing total knee replacement surgery. Researchers want to understand if the medication works differently in the blood of cancer patients compared to surgical patients, even when given the same preventive dose. The findings could help doctors better manage clot prevention for people with multiple myeloma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Saint-Etienne
RECRUITINGSaint-Etienne, 42055, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.